Robbie Marcus
Stock Analyst at JP Morgan
(3.91)
# 644
Out of 5,124 analysts
177
Total ratings
55.17%
Success rate
8.91%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $85.25 | +17.30% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $92.23 | +27.94% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $81.96 | -4.83% | 7 | Dec 5, 2025 | |
| MDT Medtronic | Maintains: Neutral | $90 → $100 | $96.06 | +4.10% | 12 | Nov 13, 2025 | |
| HTFL HeartFlow | Maintains: Overweight | $36 → $40 | $29.15 | +37.22% | 2 | Nov 13, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $40.60 | +28.08% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $10.42 | -13.63% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $89.92 | +11.21% | 7 | Nov 6, 2025 | |
| CBLL CeriBell | Maintains: Overweight | $21 → $17 | $21.93 | -22.48% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Neutral | $90 → $75 | $66.37 | +13.00% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $12.42 | +4.67% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $17.08 | -6.32% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $15.44 | +3.63% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $7.10 | -1.41% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $88.14 | +36.15% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $19.11 | +88.38% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $351.47 | +26.61% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $566.36 | +19.18% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.44 | +74.73% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $95.35 | +15.36% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $284.24 | +16.10% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $39.56 | +1.11% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $82.02 | +9.73% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $26.64 | +87.69% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $2.46 | +225.87% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $310.91 | -19.59% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.72 | +4.17% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $125.29 | -5.82% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $177.44 | -12.08% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $112.91 | -64.57% | 2 | May 5, 2020 |
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $85.25
Upside: +17.30%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $92.23
Upside: +27.94%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $81.96
Upside: -4.83%
Medtronic
Nov 13, 2025
Maintains: Neutral
Price Target: $90 → $100
Current: $96.06
Upside: +4.10%
HeartFlow
Nov 13, 2025
Maintains: Overweight
Price Target: $36 → $40
Current: $29.15
Upside: +37.22%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $40.60
Upside: +28.08%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $10.42
Upside: -13.63%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $89.92
Upside: +11.21%
CeriBell
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $21.93
Upside: -22.48%
DexCom
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $66.37
Upside: +13.00%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $12.42
Upside: +4.67%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $17.08
Upside: -6.32%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $15.44
Upside: +3.63%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $7.10
Upside: -1.41%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $88.14
Upside: +36.15%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $19.11
Upside: +88.38%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $351.47
Upside: +26.61%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $566.36
Upside: +19.18%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.44
Upside: +74.73%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $95.35
Upside: +15.36%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $284.24
Upside: +16.10%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $39.56
Upside: +1.11%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $82.02
Upside: +9.73%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $26.64
Upside: +87.69%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $2.46
Upside: +225.87%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $310.91
Upside: -19.59%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.72
Upside: +4.17%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $125.29
Upside: -5.82%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $177.44
Upside: -12.08%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $112.91
Upside: -64.57%